307
Views
3
CrossRef citations to date
0
Altmetric
REVIEW

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment

ORCID Icon, , , , &
Pages 3303-3329 | Received 18 Jul 2023, Accepted 10 Oct 2023, Published online: 25 Oct 2023

References

  • Bray GA. Evaluation of obesity. Who are the obese? Postgrad Med. 2003;114(6):19–27, 38. doi:10.3810/pgm.2003.12.1544
  • Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. PMID: 34769060. doi:10.3390/ijms222111629
  • Gutiérrez-Cuevas J, Sandoval-Rodriguez A, Meza-Rios A, et al. Molecular mechanisms of obesity-linked cardiac dysfunction: an up-date on current knowledge. Cells. 2021;10(3):629. PMID: 33809061. doi:10.3390/cells10030629
  • Boccatonda A, Andreetto L, D’Ardes D, et al. From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications. Biomedicines. 2023;11(3):883. doi:10.3390/biomedicines11030883
  • Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. World Health Organ Tech Rep Ser. 1995;854:1–452.
  • Li Z, Daniel S, Fujioka K, et al. Obesity among Asian American people in the United States: a review. Obesity. 2023;31(2):316–328. doi:10.1002/oby.23639
  • Mayoral L-C, Andrade G, Mayoral E-C, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020;151(1):11–21. doi:10.4103/ijmr.IJMR_1768_17
  • Blüher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25(8):2058–2072. PMID: 37055715. doi:10.1111/dom.15077
  • Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196. PMID: 32832560. doi:10.1155/2020/3920196
  • International Diabetes Federation. IDF DIABETES ATLAS −9th EDITION; April, 2020.
  • Strey CBM, de Carli LA, Pioner SR, et al. Impact of diabetes mellitus and insulin on nonalcoholic fatty liver disease in the morbidly obese. Ann Hepatol. 2018;17(4):585–591. doi:10.5604/01.3001.0012.0922
  • En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–2148. PMID: 37491159. doi:10.1136/gutjnl-2023-330110
  • Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209. doi:10.1016/j.jhep.2020.03.039
  • Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919. doi:10.1007/s12072-020-10094-2
  • Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023;101133:101133. doi:10.1016/j.aohep.2023.101133
  • Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651. doi:10.1038/s41575-022-00635-5
  • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
  • Targher G. Concordance of MAFLD and NAFLD diagnostic criteria in “real-world” data. Liver Int. 2020;40:2879–2880. doi:10.1111/liv.14623
  • Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: focusing on the non‐overlap groups. Liver Int. 2021;42(2):277–287. doi:10.1111/liv.15139
  • Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. PMID: 30902670. doi:10.1016/S2468-1253(19)30039-1
  • Liu J, Mu C, Li K, Luo H, Liu Y, Li Z. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. Int J Public Health. 2021;66:1604371. PMID: 34690666. doi:10.3389/ijph.2021.1604371
  • Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573–e582. PMID: 33618024. doi:10.1016/j.cgh.2021.02.030
  • Wu X, Cheung CKY, Ye D, et al. Serum thrombospondin-2 levels are closely associated with the severity of metabolic syndrome and metabolic associated fatty liver disease. J Clin Endocrinol Metab. 2022;107(8):e3230–e3240. PMID: 35532410. doi:10.1210/clinem/dgac292
  • Moreno-Vedia J, Girona J, Ibarretxe D, Masana L, Rodríguez-Calvo R. Unveiling the role of the fatty acid binding protein 4 in the metabolic-associated fatty liver disease. Biomedicines. 2022;10(1):197. PMID: 35052876. doi:10.3390/biomedicines10010197
  • Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–3030. PMID: 32997882. doi:10.1111/liv.14675
  • Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41(6):1290–1293. PMID: 33590934. doi:10.1111/liv.14828
  • Tsutsumi T, Nakano D, Hashida R, et al. The inter-organ crosstalk reveals an inevitable link between MAFLD and extrahepatic diseases. Nutrients. 2023;15(5):1123. doi:10.3390/nu15051123
  • Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17(1):40–52. doi:10.1038/s41575-019-0212-0
  • Di Renzo L, Sarlo F, Petramala L, et al. Association between −308 G/A TNF- α polymorphism and appendicular skeletal muscle mass index as a marker of sarcopenia in normal weight obese syndrome. Dis Markers. 2013;35(6):615–623. doi:10.1155/2013/983424
  • Jia A, Xu S, Xing Y, et al. Prevalence and cardiometabolic risks of normal weight obesity in Chinese population: a nationwide study. Nutr Metab Cardiovasc Dis. 2018;28(10):1045–1053. doi:10.1016/j.numecd.2018.06.015
  • Lonardo A, Mantovani A, Lugari S, et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19(4):359–366. doi:10.1016/j.aohep.2020.03.001
  • Di Renzo L, Galvano F, Orlandi C, et al. Oxidative stress in normal-weight obese syndrome. Obesity. 2010;18(11):2125–2130. doi:10.1038/oby.2010.50
  • Di Renzo L, Del Gobbo V, Bigioni M, Premrov MG, Cianci R, De Lorenzo A. Body composition analyses in normal weight obese women. Eur Rev Med Pharmacol Sci. 2006;10(4):191–196.
  • Mathew H, Farr OM, Mantzoros CS. Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism. 2016;65(1):73–80. doi:10.1016/j.metabol.2015.10.019
  • Højland Ipsen D, Tveden-Nyborg P, Lykkesfeldt J. Normal weight dyslipidemia: is it all about the liver? Obesity. 2016;24(3):556–567. doi:10.1002/oby.21443
  • Mannisto S, Harald K, Kontto J, et al. Dietary and lifestyle characteristics associated with normal-weight obesity: the National FINRISK 2007 Study. Br J Nutr. 2014;111(5):887–894. doi:10.1017/S0007114513002742
  • Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699–713. doi:10.2337/diabetes.47.5.699
  • De Lorenzo A, Del Gobbo V, Premrov MG, et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr. 2007;85(1):40–45. doi:10.1093/ajcn/85.1.40
  • Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–949. doi:10.1161/01.RES.0000163635.62927.34
  • Lee S-H, Han K, Yang HK, et al. A novel criterion for identifying metabolically obese but normal weight individuals using the product of triglycerides and glucose. Nutr Diabetes. 2015;5(4):e149. doi:10.1038/nutd.2014.46
  • Brandao I, Martins MJ, Monteiro R. Metabolically healthy obesity-heterogeneity in definitions and unconventional factors. Metabolites. 2020;10(2):48. doi:10.3390/metabo10020048
  • Shaharyar S, Roberson LL, Jamal O, et al. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated C-reactive protein and hepatic steatosis in a large healthy Brazilian population. J Obes. 2015;2015:178526. doi:10.1155/2015/178526
  • Iacobini C, Pugliese G, Blasetti Fantauzzi C, et al. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51–60. doi:10.1016/j.metabol.2018.11.009
  • Munoz-Garach A, Cornejo-Pareja I, Tinahones FJ. Does metabolically healthy obesity exist? Nutrients. 2016;8(6):320. doi:10.3390/nu8060320
  • Lin H, Zhang L, Zheng R, et al. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: a PRISMA-compliant article. Medicine (Baltimore). 2017;96(47):e8838. doi:10.1097/MD.0000000000008838
  • Perreault M, Zulyniak MA, Badoud F, et al. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One. 2014;9(2):e88539. doi:10.1371/journal.pone.0088539
  • Ferrer R, Pardina E, Rossell J, et al. Morbidly “Healthy” obese are not metabolically healthy but less metabolically imbalanced than those with type 2 diabetes or dyslipidemia. Obes Surg. 2015;25(8):1380–1391. doi:10.1007/s11695-014-1528-z
  • Doumatey AP, Zhou J, Zhou M, et al. pro-inflammatory and lipid biomarkers mediate metabolically healthy obesity: a proteomics study. Obesity. 2016;24(6):1257–1265. doi:10.1002/oby.21482
  • Tanriover C, Copur S, Gaipov A, et al. Metabolically healthy obesity: misleading phrase or healthy phenotype? Eur J Intern Med. 2023;111:5–20. doi:10.1016/j.ejim.2023.02.025
  • De Lorenzo A, Soldati L, Sarlo F, et al. New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol. 2016;22(2):681–703. doi:10.3748/wjg.v22.i2.681
  • Dobson R, Burgess MI, Sprung VS, et al. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes. 2016;40(1):153–161. doi:10.1038/ijo.2015.151
  • Marques-Vidal P, Bochud M, Bastardot F, et al. Association between inflammatory and obesity markers in a Swiss population-based sample (CoLaus Study). Obes Facts. 2012;5(5):734–744. doi:10.1159/000345045
  • Mamtani M, Kulkarni H, Dyer TD, et al. Genome- and epigenome-wide association study of hypertriglyceridemic waist in Mexican American families. Clin Epigenetics. 2016;8(1):6. doi:10.1186/s13148-016-0173-x
  • Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016;7(3):312–321. doi:10.1002/jcsm.12076
  • Abellan van Kan G, Houles M, Vellas B. Identifying sarcopenia. Curr Opin Clin Nutr Metab Care. 2012;15(5):436–441. doi:10.1097/MCO.0b013e328356bbf4
  • Perna S, Spadaccini D, Rondanelli M. Sarcopenic obesity: time to target the phenotypes. J Cachexia Sarcopenia Muscle. 2019;10(3):710–711. doi:10.1002/jcsm.12425
  • Kim JH, Cho JJ, Park YS. Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score. J Korean Med Sci. 2015;30(3):264–271. doi:10.3346/jkms.2015.30.3.264
  • Yang CW, Li CI, Li TC, et al. Association of sarcopenic obesity with higher serum high-sensitivity C-reactive protein levels in Chinese older males--a community-based study (Taichung Community Health Study-Elderly, TCHS-E) [published correction appears in PLoS One. 2015;10(8):e0136069]. PLoS One. 2015;10(7):e0132908. PMID: 26177029. doi:10.1371/journal.pone.0132908
  • Perna S, Spadaccini D, Nichetti M, Avanzato I, Faliva MA, Rondanelli M. Osteosarcopenic visceral obesity and osteosarcopenic subcutaneous obesity, two new phenotypes of sarcopenia: prevalence, metabolic profile, and risk factors. J Aging Res. 2018;2018:6147426. PMID: 29862078. doi:10.1155/2018/6147426
  • Shimabukuro M. Leptin resistance and lipolysis of white adipose tissue: an implication to ectopic fat disposition and its consequences. J Atheroscler Thromb. 2017;24(11):1088–1089. doi:10.5551/jat.ED083
  • Fan X, Yuan W, Huang W, et al. Recent progress in leptin signaling from a structural perspective and its implications for diseases. Biochimie. 2023;212:60–75. doi:10.1016/j.biochi.2023.04.011
  • Haskins IN, Chang J, Nor Hanipah Z, et al. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease? Surg Obes Relat Dis. 2018;14(3):342–346. doi:10.1016/j.soard.2017.11.032
  • Sung KC, Cha S-C, Sung J-W, et al. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24(3):256–262. doi:10.1016/j.numecd.2013.07.005
  • Lonardo A, Bellentani S, Argo CK, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. doi:10.1016/j.dld.2015.08.004
  • Rinaldi L, Nascimbeni F, Giordano M, et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol. 2017;23(8):1458–1468. doi:10.3748/wjg.v23.i8.1458
  • Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
  • Badmus OO, Hinds TD, Stec DE. Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease [published online ahead of print, 2023 May 16]. Curr Hypertens Rep. 2023. doi:10.1007/s11906-023-01242-8
  • Foster M, Pagliassotti M. Metabolic alterations following visceral fat removal and expansion: beyond anatomic location. Adipocyte. 2012;1(4):192–199. PMID: 23700533. doi:10.4161/adip.21756
  • Hernández-Conde M, Llop E, Carrillo C, et al. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(42):6658–6668. PMID: 33268953. doi:10.3748/wjg.v26.i42.6658
  • Drozdz K, Nabrdalik K, Hajzler W, et al. Metabolic-Associated Fatty Liver Disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota. Nutrients. 2021;14(1):103. doi:10.3390/nu14010103
  • Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol. 2015;63(2):462–469. doi:10.1016/j.jhep.2015.03.032
  • Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58(9):1281–1288. doi:10.1136/gut.2008.151977
  • Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol. 2017;23(36):6571–6592. doi:10.3748/wjg.v23.i36.6571
  • Stender S, Kozlitina J, Nordestgaard BG, et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49(6):842–847. doi:10.1038/ng.3855
  • Musio A, Perazza F, Leoni L, et al. Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease. Int J Mol Sci. 2023;24(8). doi:10.3390/ijms24087517
  • Chun HS, Lee M, Lee HA, et al. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(9):2298–2307.e18. doi:10.1016/j.cgh.2022.11.031
  • Choe EY, Lee Y-H, Choi YJ, et al. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. J Gastroenterol Hepatol. 2018;33(5):1082–1091. doi:10.1111/jgh.14011
  • Shi Y-X, Chen X-Y, Qiu H-N, et al. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity. Scand J Gastroenterol. 2021;56(3):312–320. doi:10.1080/00365521.2021.1879244
  • Gan D, Wang L, Jia M, et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. Clin Nutr. 2020;39(4):1124–1130. doi:10.1016/j.clnu.2019.04.023
  • Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752. doi:10.1016/S2468-1253(20)30077-7
  • Ito T, Ishigami M, Zou B, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. Hepatol Int. 2021;15(2):366–379. doi:10.1007/s12072-021-10143-4
  • Leung JC, Loong TC-W, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65(1):54–64. doi:10.1002/hep.28697
  • Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54(6):1244–1249. doi:10.1016/j.jhep.2010.09.037
  • Weinberg EM, Trinh HN, Firpi RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clin Gastroenterol Hepatol. 2021;19(5):996–1008.e6. doi:10.1016/j.cgh.2020.06.066
  • Tang A, Ng CH, Phang PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD - a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1750–1760.e12. doi:10.1016/j.cgh.2022.06.029
  • Xie X, Guo B, Xiao X, et al. Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study. BMC Public Health. 2022;22(1):118. doi:10.1186/s12889-021-12486-x
  • Amani R, Parohan M, Jomehzadeh N, et al. Dietary and biochemical characteristics associated with normal-weight obesity. Int J Vitam Nutr Res. 2019;89(5–6):331–336. doi:10.1024/0300-9831/a000477
  • Enjoji M, Yasutake K, Kohjima M, et al. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol. 2012;2012:925807. doi:10.1155/2012/925807
  • Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: a Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology. 2020;71(4):1213–1227. doi:10.1002/hep.30908
  • Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187–196. doi:10.1038/nature14132
  • Fehlert E, Wagner R, Ketterer C, et al. Genetic determination of body fat distribution and the attributive influence on metabolism. Obesity. 2017;25(7):1277–1283. doi:10.1002/oby.21874
  • Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17–26. doi:10.1038/ng.3714
  • Wei JL, Leung JC-F, Loong TC-W, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110(9):1306–14; quiz 1315. doi:10.1038/ajg.2015.235
  • Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15(10):1604–1611.e1. doi:10.1016/j.cgh.2017.04.045
  • Eslam M, Mangia A, Berg T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64(1):34–46. doi:10.1002/hep.28475
  • Meroni M, Longo M, Lombardi R, et al. Low Lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2022;6(3):535–549. doi:10.1002/hep4.1830
  • Petta S, Valenti L, Tuttolomondo A, et al. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology. 2017;66(6):1885–1893. doi:10.1002/hep.29395
  • Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
  • Bjorkstrom K, Stål P, Hultcrantz R, et al. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(9):1461–1468. doi:10.1016/j.cgh.2017.04.040
  • Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73(2):263–276. doi:10.1016/j.jhep.2020.03.006
  • Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283(4):356–370. doi:10.1111/joim.12719
  • Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–1123. doi:10.1016/j.metabol.2016.05.003
  • Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913–1931. doi:10.1016/j.clnu.2022.06.037
  • Gepner Y, Shelef I, Komy O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379–388. doi:10.1016/j.jhep.2019.04.013
  • Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):475–494. doi:10.1016/j.jhep.2013.02.012
  • Riebe D, Franklin BA, Thompson PD, et al. Updating ACSM’s recommendations for exercise preparticipation health screening. Med Sci Sports Exerc. 2015;47(11):2473–2479. doi:10.1249/MSS.0000000000000664
  • Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. doi:10.1016/S0140-6736(15)00803-X
  • Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124. doi:10.1056/NEJMoa2028395
  • Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49(1):80–86. doi:10.1002/hep.22575
  • Feng X, Lin Y, Zhuo S, et al. Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: a randomized controlled trial. Am J Clin Nutr. 2023;117(4):691–700. doi:10.1016/j.ajcnut.2023.02.008
  • Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2018;9(1):90–96. doi:10.3892/br.2018.1100
  • Gaur S, Levy S, Mathus-Vliegen L, et al. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015;81(6):1330–1336. doi:10.1016/j.gie.2015.01.054
  • Bazerbachi F, Haffar S, Sawas T, et al. Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg. 2018;28(9):2617–2625. doi:10.1007/s11695-018-3227-7
  • Popov VB, Thompson CC, Kumar N, et al. Effect of intragastric balloons on liver enzymes: a systematic review and meta-analysis. Dig Dis Sci. 2016;61(9):2477–2487. doi:10.1007/s10620-016-4178-2
  • Chandan S, Mohan BP, Khan SR, et al. Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a comprehensive review and meta-analysis. Obes Surg. 2021;31(3):1271–1279. doi:10.1007/s11695-020-05084-0
  • Lopez-Nava G, Galvão MP, Bautista-Castaño I, et al. Endoscopic Sleeve gastroplasty: how I do it? Obes Surg. 2015;25(8):1534–1538. doi:10.1007/s11695-015-1714-7
  • Hajifathalian K, Mehta A, Ang B, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc. 2021;93(5):1110–1118. doi:10.1016/j.gie.2020.08.023
  • van Baar A, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295–303. doi:10.1136/gutjnl-2019-318349
  • de Oliveira G, de Moura DTH, Funari MP, et al. Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis. Obes Surg. 2021;31(3):1304–1312. doi:10.1007/s11695-020-05170-3
  • Benaiges D, Más-Lorenzo A, Goday A, et al. Laparoscopic sleeve gastrectomy: more than a restrictive bariatric surgery procedure? World J Gastroenterol. 2015;21(41):11804–11814. doi:10.3748/wjg.v21.i41.11804
  • Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis. 2019;15(12):2123–2130. doi:10.1016/j.soard.2019.09.060
  • Salman MA, Salman AA, Abdelsalam A, et al. Laparoscopic sleeve gastrectomy on the horizon as a promising treatment modality for NAFLD. Obes Surg. 2020;30(1):87–95. doi:10.1007/s11695-019-04118-6
  • Bjorklund P, Laurenius A, Een E, et al. Is the Roux limb a determinant for meal size after gastric bypass surgery? Obes Surg. 2010;20(10):1408–1414. doi:10.1007/s11695-010-0192-1
  • Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023;29(suppl):S5–S16. doi:10.3350/cmh.2022.0424
  • Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023;20(7):475–494. doi:10.1038/s41569-023-00847-5
  • Li C, Ford ES, Zhao G, et al. Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr. 2009;90(6):1457–1465. doi:10.3945/ajcn.2009.28141
  • Chackrewarthy S, Gunasekera D, Pathmeswaren A, et al. A comparison between revised NCEP ATP III and IDF definitions in diagnosing metabolic syndrome in an urban Sri Lankan population: the Ragama Health Study. ISRN Endocrinol. 2013;2013:320176. doi:10.1155/2013/320176
  • Oliveros E, Somers VK, Sochor O, et al. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56(4):426–433. doi:10.1016/j.pcad.2013.10.003
  • Madeira FB, Silva AA, Veloso HF, et al. Normal weight obesity is associated with metabolic syndrome and insulin resistance in young adults from a middle-income country. PLoS One. 2013;8(3):e60673. doi:10.1371/journal.pone.0060673
  • Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol. 2013;2013:204164. doi:10.1155/2013/204164
  • Kang S, Kyung C, Park JS, et al. Subclinical vascular inflammation in subjects with normal weight obesity and its association with body fat: an 18 F-FDG-PET/CT study. Cardiovasc Diabetol. 2014;13:70. doi:10.1186/1475-2840-13-70
  • April-Sanders AK, Rodriguez CJ. Metabolically healthy obesity redefined. JAMA Netw Open. 2021;4(5):e218860. doi:10.1001/jamanetworkopen.2021.8860
  • Bradshaw PT, Monda KL, Stevens J. Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the atherosclerosis risk in communities study. Obesity. 2013;21(1):203–209. doi:10.1002/oby.20248
  • Hoddy KK, Axelrod CL, Mey JT, et al. Insulin resistance persists despite a metabolically healthy obesity phenotype. Obesity. 2022;30(1):39–44. PMID: 34816598. doi:10.1002/oby.23312
  • Li X, Ren Y, Chang K, et al. Adipose tissue macrophages as potential targets for obesity and metabolic diseases. Front Immunol. 2023;14:1153915. doi:10.3389/fimmu.2023.1153915
  • Guria S, Hoory A, Das S, et al. Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play. Biosci Rep. 2023;43(3). doi:10.1042/BSR20220200
  • Esser N, L’homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia. 2013;56(11):2487–2497. doi:10.1007/s00125-013-3023-9
  • Alalwan TA. Phenotypes of sarcopenic obesity: exploring the effects on peri-muscular fat, the obesity paradox, hormone-related responses and the clinical implications. Geriatrics (Basel). 2020;5(1):8. doi:10.3390/geriatrics5010008
  • Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–537. doi:10.1038/s41574-018-0062-9
  • Hamaguchi Y, Kaido T, Okumura S, et al. Preoperative visceral adiposity and muscularity predict poor outcomes after hepatectomy for hepatocellular carcinoma. Liver Cancer. 2019;8(2):92–109. doi:10.1159/000488779
  • Lee SH, Yang HK, Ha H-S, et al. Changes in metabolic health status over time and risk of developing type 2 diabetes: a prospective cohort study. Medicine (Baltimore). 2015;94(40):e1705. doi:10.1097/MD.0000000000001705
  • Hamer M, Bell JA, Sabia S, et al. Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing. Eur J Endocrinol. 2015;173(5):703–708. doi:10.1530/EJE-15-0449
  • Bell JA, Hamer M, Sabia S, et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 2015;65(1):101–102. doi:10.1016/j.jacc.2014.09.077
  • Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
  • Kushner RF, Kahan S. Introduction: the State of Obesity in 2017. Med Clin North Am. 2018;102(1):1–11. doi:10.1016/j.mcna.2017.08.003
  • Pang Q, Zhang JY, Song SD, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol. 2015;21(5):1650–1662. doi:10.3748/wjg.v21.i5.1650
  • Chang Y, Jung H-S, Cho J, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111(8):1133–1140. doi:10.1038/ajg.2016.178
  • Bhaskaran K, dos-Santos-Silva I, Leon DA, et al. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–953. doi:10.1016/S2213-8587(18)30288-2
  • Argo CK, Stine JG, Henry ZH, et al. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2018;48(3):290–299. doi:10.1111/apt.14803
  • Zhang S, Du T, Li M, et al. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. Medicine (Baltimore). 2017;96(12):e6381. doi:10.1097/MD.0000000000006381
  • Liu DJ, Peloso GM, Yu H, et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017;49(12):1758–1766. doi:10.1038/ng.3977
  • Kim Y, Chang Y, Cho YK, et al. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 2019;39(10):1884–1894. doi:10.1111/liv.14184
  • Gutierrez-Grobe Y, Juárez-Hernández E, Sánchez-Jiménez BA, et al. Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease. Diabetes Metab. 2017;43(4):332–337. doi:10.1016/j.diabet.2017.02.007
  • Ampuero J, Aller R, Gallego‐Durán R, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11–12):1260–1270. doi:10.1111/apt.15015
  • Lee MJ, Kim E-H, Bae S-J, et al. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study. Gut Liver. 2019;13(1):67–76. doi:10.5009/gnl18070
  • Kim G, Lee S-E, Lee Y-B, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology. 2018;68(5):1755–1768. doi:10.1002/hep.30049
  • Hyun Kim K, Kyung Kim B, Yong Park J, et al. Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. Eur J Gastroenterol Hepatol. 2020;32(1):58–65. doi:10.1097/MEG.0000000000001475
  • Chun HS, Kim MN, Lee JS, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2021;12(5):1168–1178. doi:10.1002/jcsm.12754
  • Rigor J, Vasconcelos R, Lopes R, Moreira T, Barata P, Martins-Mendes D. Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease [published online ahead of print, 2022 Mar 28]. Minerva Gastroenterol (Torino). 2022. doi:10.23736/S2724-5985.22.03097-2
  • Petermann-Rocha F, Gray SR, Forrest E, et al. Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants. J Hepatol. 2022;76(5):1021–1029. doi:10.1016/j.jhep.2022.01.010
  • Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568. doi:10.1136/gutjnl-2019-318813
  • Golabi P, Paik JM, Arshad T, et al. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun. 2020;4(8):1136–1148. doi:10.1002/hep4.1534
  • Li C, Guo P, Okekunle AP, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34(1):256–262. doi:10.1111/jgh.14360
  • Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2):85–95. doi:10.1111/apt.14112
  • Zeng J, Yang R-X, Sun C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020;26(15):1792–1804. doi:10.3748/wjg.v26.i15.1792
  • Hagstrom H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2(1):48–57. doi:10.1002/hep4.1124
  • Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382–390. doi:10.1136/gutjnl-2020-322564
  • Wei L, Cheng X, Luo Y, et al. Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: a cohort study. Diabetes Metab. 2021;47(3):101200. doi:10.1016/j.diabet.2020.08.008
  • Zou B, Yeo YH, Nguyen VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020;288(1):139–151. doi:10.1111/joim.13069
  • Golabi P, Paik J, Fukui N, et al. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65–72. doi:10.2337/cd18-0026
  • Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–642. doi:10.1007/s00125-005-1682-x
  • Denkmayr L, Feldman A, Stechemesser L, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018;7(12):562. doi:10.3390/jcm7120562
  • Wang Q, You H, Ou X, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatol Int. 2019;13(6):766–776. doi:10.1007/s12072-019-09982-z
  • Gujral UP, Vittinghoff E, Mongraw-Chaffin M, et al. Cardiometabolic abnormalities among normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med. 2017;166(9):628–636. doi:10.7326/M16-1895
  • Tabung FK, Steck SE, Zhang J, et al. Construct validation of the dietary inflammatory index among postmenopausal women. Ann Epidemiol. 2015;25(6):398–405. doi:10.1016/j.annepidem.2015.03.009
  • Ji Y, Yiorkas AM, Frau F, et al. Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes. 2019;68(1):207–219. doi:10.2337/db18-0708
  • Yaghootkar H, Lotta LA, Tyrrell J, et al. Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart disease. Diabetes. 2016;65(8):2448–2460. doi:10.2337/db15-1671
  • Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–279. doi:10.1016/j.jhep.2017.09.003
  • Bale G, Vishnubhotla RV, Mitnala S, et al. Whole-exome sequencing identifies a variant in phosphatidylethanolamine N-methyltransferase gene to be associated with lean-nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(5):561–568. doi:10.1016/j.jceh.2019.02.001
  • Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99–114. doi:10.1038/nrendo.2017.173
  • Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170. doi:10.1016/j.metabol.2020.154170
  • Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol. 2019;56(4):385–396. doi:10.1007/s00592-018-1266-0
  • Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612. doi:10.1038/s41575-021-00448-y
  • Jeeyavudeen MS, Khan SK, Fouda S, et al. Management of metabolic-associated fatty liver disease: the diabetology perspective. World J Gastroenterol. 2023;29(1):126–143. doi:10.3748/wjg.v29.i1.126
  • Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962–969. doi:10.1136/gutjnl-2020-322572
  • Morrison AE, Zaccardi F, Khunti K, et al. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis. Liver Int. 2019;39(3):557–567. doi:10.1111/liv.13994
  • Nasr P, Ignatova S, Kechagias S, et al. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2(2):199–210. doi:10.1002/hep4.1134
  • Nasr P, Fredrikson M, Ekstedt M, et al. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020;40(5):1069–1078. doi:10.1111/liv.14414
  • Bae JC, Han JM, Cho JH, et al. The persistence of fatty liver has a differential impact on the development of diabetes: the Kangbuk Samsung Health Study. Diabetes Res Clin Pract. 2018;135:1–6. doi:10.1016/j.diabres.2017.10.019
  • Lee J, Cho YK, Kang YM, et al. The impact of NAFLD and waist circumference changes on diabetes development in prediabetes subjects. Sci Rep. 2019;9(1):17258. doi:10.1038/s41598-019-53947-z
  • Cho HJ, Hwang S, Park JI, et al. Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus. Gut Liver. 2019;13(4):440–449. doi:10.5009/gnl18382
  • Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98(9):3637–3643. doi:10.1210/jc.2013-1519
  • Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684–694. doi:10.1016/S2213-8587(19)30187-1
  • Zaharia OP, Strassburger K, Knebel B, et al. Role of patatin-like phospholipase domain-containing 3 gene for hepatic lipid content and insulin resistance in diabetes. Diabetes Care. 2020;43(9):2161–2168. doi:10.2337/dc20-0329
  • Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, et al. Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss. Cell Metab. 2020;31(2):233–249.e4. doi:10.1016/j.cmet.2019.11.018
  • Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64. doi:10.1016/j.jhep.2014.12.012
  • Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147
  • Heymsfield SB, Wadden TA, Longo DL. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(15):1492. doi:10.1056/NEJMra1514009
  • Hashem A, Khalouf A, Acosta A. Management of obesity and nonalcoholic fatty liver disease: a literature review. Semin Liver Dis. 2021;41(4):435–447. doi:10.1055/s-0041-1731704
  • Stefano JT, Duarte SMB, Ribeiro Leite Altikes RG, et al. Non-pharmacological management options for MAFLD: a practical guide. Ther Adv Endocrinol Metab. 2023;14:20420188231160394. doi:10.1177/20420188231160394
  • Chai XN, Zhou B-Q, Ning N, et al. Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1081096. doi:10.3389/fendo.2023.1081096
  • Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904. doi:10.1007/s00125-011-2446-4
  • Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5; quiz e14–5. doi:10.1053/j.gastro.2015.04.005
  • Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. doi:10.1016/j.jacc.2013.11.004
  • Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129(8):879.e1–6. doi:10.1016/j.amjmed.2016.02.009
  • Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. doi:10.1016/j.eclinm.2023.101882
  • Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates. Biomedicines. 2022;10(2):274. doi:10.3390/biomedicines10020274
  • Sangro P, de la Torre Aláez M, Sangro B, D’Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment [published online ahead of print, 2023 Mar 28]. J Physiol Biochem. 2023. doi:10.1007/s13105-023-00954-4
  • Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260. doi:10.3389/fendo.2022.1087260
  • Maestri M, Santopaolo F, Pompili M, et al. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies. Front Nutr. 2023;10:1110536. doi:10.3389/fnut.2023.1110536
  • Ali MR, Moustarah F, Kim JJ. American society for metabolic and bariatric surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Obes Relat Dis. 2016;12(3):462–467. doi:10.1016/j.soard.2015.12.026
  • NASH News March. 2021—Recognizing NASH patient advocacy. Available from: https://www.globalliver.org/news/2021/nash-news-march. Accessed April 5, 2021
  • Lazaridis II, Delko T. Bariatric surgery and metabolic dysfunction-associated fatty liver disease: a 2022 update. Praxis. 2023;112(2):97–102. doi:10.1024/1661-8157/a003969
  • Lassailly G, Caiazzo R, Ntandja-Wandji L-C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290–1301.e5. doi:10.1053/j.gastro.2020.06.006
  • Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–511. doi:10.1016/j.soard.2018.12.002